Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction.
作者信息
Reddy Yogesh N V, Melenovsky Vojtech, Asokan Aneesh K, Haluzik Martin, Carter Rickey E, Nair Sreekumaran, Jensen Michael D, Borlaug Barry A
机构信息
The Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
出版信息
Eur Heart J. 2024 Oct 5;45(37):3889-3891. doi: 10.1093/eurheartj/ehae534.
Abstract
摘要
相似文献
1
Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction.达格列净、肽YY与射血分数保留的心力衰竭患者的体重减轻
Eur Heart J. 2024 Oct 5;45(37):3889-3891. doi: 10.1093/eurheartj/ehae534.
2
Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial.达格列净与射血分数保留的心力衰竭患者右心室-肺血管相互作用：一项随机临床试验的二次分析
JAMA Cardiol. 2024 Sep 1;9(9):843-851. doi: 10.1001/jamacardio.2024.1914.
3
Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction.达格列净对射血分数保留的心力衰竭患者身体成分的影响及其与血流动力学的关系。
Circulation. 2024 Jun 18;149(25):2026-2028. doi: 10.1161/CIRCULATIONAHA.124.069479. Epub 2024 Jun 17.
4
Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.达格列净和恩格列净对射血分数保留和降低的心衰患者 6 分钟步行距离的影响：一项纳入 2624 例患者的随机对照试验的系统评价和荟萃分析。
Eur J Clin Pharmacol. 2024 Jul;80(7):951-963. doi: 10.1007/s00228-024-03660-2. Epub 2024 Mar 18.
5
Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial.钠-葡萄糖协同转运蛋白2抑制剂联合或不联合醛固酮拮抗剂用于射血分数保留的心力衰竭：SOGALDI-PEF试验
J Am Coll Cardiol. 2025 Aug 5;86(5):320-333. doi: 10.1016/j.jacc.2025.05.033.
6
Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.恩格列净和其他 SGLT2 抑制剂在射血分数保留的心力衰竭患者中的应用：系统评价和荟萃分析。
Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447241289067. doi: 10.1177/17539447241289067.
7
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.英国国家卫生与临床优化研究所关于达格列净用于射血分数降低的慢性心力衰竭的指南。
Lancet Diabetes Endocrinol. 2021 May;9(5):261-263. doi: 10.1016/S2213-8587(21)00072-3. Epub 2021 Mar 10.
8
Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial.达格列净增强射血分数保留的心力衰竭患者运动时的动脉和静脉顺应性：来自 CAMEO-DAPA 试验的见解。
Circulation. 2024 Sep 24;150(13):997-1009. doi: 10.1161/CIRCULATIONAHA.124.068788. Epub 2024 Aug 5.
9
Letter to the editor: "Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials involving 2624 patients".致编辑的信：“达格列净和恩格列净对射血分数保留和降低的心力衰竭患者6分钟步行距离的影响：一项涉及2624例患者的随机对照试验的系统评价和荟萃分析”
Eur J Clin Pharmacol. 2024 Nov;80(11):1841-1842. doi: 10.1007/s00228-024-03731-4. Epub 2024 Jul 21.
10
The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.钠-葡萄糖协同转运蛋白 2 抑制剂对射血分数保留的心力衰竭患者心血管结局的影响。
Ann Pharmacother. 2024 May;58(5):506-513. doi: 10.1177/10600280231189508. Epub 2023 Aug 5.
引用本文的文献
1
Physiologic Phenotyping of Responses to Exercise and Activity in Heart Failure.心力衰竭患者对运动和活动反应的生理表型分析
Circ Res. 2025 Jul 7;137(2):290-315. doi: 10.1161/CIRCRESAHA.125.325534. Epub 2025 Jul 3.
2
Left Heart Abnormalities in Patients With Lung Disease, OSA, and Chronic Thromboemboli at Risk for or With Known Pulmonary Hypertension.患有肺部疾病、阻塞性睡眠呼吸暂停（OSA）以及有肺动脉高压风险或已知患有肺动脉高压的慢性血栓栓塞患者的左心异常。
Circ Heart Fail. 2025 Aug;18(8):e012912. doi: 10.1161/CIRCHEARTFAILURE.125.012912. Epub 2025 May 29.
3
Treatment options for heart failure in individuals with overweight or obesity: a review.超重或肥胖个体心力衰竭的治疗选择：一项综述
Future Cardiol. 2025 Apr;21(5):315-329. doi: 10.1080/14796678.2025.2479378. Epub 2025 Mar 18.
本文引用的文献
1
Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial.达格列净与射血分数保留的心力衰竭患者右心室-肺血管相互作用：一项随机临床试验的二次分析
JAMA Cardiol. 2024 Sep 1;9(9):843-851. doi: 10.1001/jamacardio.2024.1914.
2
Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction.达格列净对射血分数保留的心力衰竭患者身体成分的影响及其与血流动力学的关系。
Circulation. 2024 Jun 18;149(25):2026-2028. doi: 10.1161/CIRCULATIONAHA.124.069479. Epub 2024 Jun 17.
3
Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.达格列净对射血分数保留的心力衰竭的心脏和代谢影响：CAMEO-DAPA 试验。
Circulation. 2023 Sep 5;148(10):834-844. doi: 10.1161/CIRCULATIONAHA.123.065134. Epub 2023 Aug 3.
4
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.SGLT2 抑制剂对肾小管钠、水和氯稳态的影响及其影响心力衰竭结局的作用的批判性分析。
Circulation. 2023 Jul 25;148(4):354-372. doi: 10.1161/CIRCULATIONAHA.123.064346. Epub 2023 Jul 24.
5
Dapagliflozin for heart failure according to body mass index: the DELIVER trial.达格列净治疗心力衰竭与体重指数的相关性：DELIVER 试验。
Eur Heart J. 2022 Nov 1;43(41):4406-4417. doi: 10.1093/eurheartj/ehac481.
6
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.恩格列净对心力衰竭循环蛋白质组学的影响：对 EMPEROR 计划的机制见解。
Eur Heart J. 2022 Dec 21;43(48):4991-5002. doi: 10.1093/eurheartj/ehac495.
7
LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.LX4211 通过减少钠/葡萄糖协同转运蛋白 1（SGLT1）介导的肠道葡萄糖吸收，增加血清胰高血糖素样肽 1 和肽 YY 水平。
J Pharmacol Exp Ther. 2013 May;345(2):250-9. doi: 10.1124/jpet.113.203364. Epub 2013 Mar 13.
8
Long-term persistence of hormonal adaptations to weight loss.体重减轻引起的激素适应的长期持续。
N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056/NEJMoa1105816.
9
Inhibition of food intake in obese subjects by peptide YY3-36.肽YY3-36对肥胖受试者食物摄入的抑制作用。
N Engl J Med. 2003 Sep 4;349(10):941-8. doi: 10.1056/NEJMoa030204.
10
Gut hormone PYY(3-36) physiologically inhibits food intake.肠道激素PYY(3-36)在生理上抑制食物摄入。
Nature. 2002 Aug 8;418(6898):650-4. doi: 10.1038/nature00887.
Zotero 插件